AAPG Stock Analysis: Buy, Sell, or Hold?
AAPG - Ascentage Pharma Group International American Depository Shares
$19.97
1.07 (5.66%)
▲
5d:
+7.95%
30d:
+16.65%
90d:
-24.81%
HOLD
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 19, 2026
Get Alerted When AAPG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: AAPG is 7.4% above its trading range ($18.59). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: AAPG is 7.4% above its trading range ($18.59). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: AAPG is currently trading at $19.97, which is considered extended relative to its 30-day fair value range of $16.87 to $18.59.
Technical Outlook: Technically, AAPG is in a strong downtrend. The price is approaching resistance at $19.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: AAPG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $47.56 (+138.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AAPG is in a strong downtrend. The price is approaching resistance at $19.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: AAPG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $47.56 (+138.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$16.87 -
$18.59
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.7%)
- BULLISH: Trading 138.1% below Wall St target ($47.56)
- CAUTION: Extended 7.4% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$16.87 -
$18.59
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.36
Resistance Level
$19.97
Current Trend
Strong Downtrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.78
Wall Street Target
$47.56
(+138.1%)
Revenue Growth (YoY)
117.0%
Profit Margin
-216.5%
Share & Embed Analysis
Last updated: July 13, 2026 2:06 AM ET
Data refreshes hourly during market hours. Next update: 3:06 AM
Data refreshes hourly during market hours. Next update: 3:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AAPG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
